Geneticure is fulfilling the promise of personalized medicine.

For the past decade, we’ve put science and innovation to work, taking personalized medicine to the next level. Our unique focus on the physiology and combinatorial pharmacogenomics specific to each disease is unparalleled in a field of shotgun approaches to personalized medicine. Our first solution is solving the trial-and-error approach in the leading preventable cause of death in the world: hypertension or high blood pressure. And we’re just getting started.

Our technology goes beyond the way medications are metabolized.

We examine disease-specific drug targets in DNA that influence outcome variables in high blood pressure. With our patented genetic testing, unique algorithms, and healthcare provider’s insight, we can partner to optimize the healthcare path.

Our leadership.

Meet the team that drives our path toward growth and success as we continue to help make positive advancements in science and pharmacogenomics.

Eric Snyder, PhD

CHIEF OPERATING OFFICER

Dr. Snyder completed his PhD at the University of Minnesota and performed his research training at Mayo Clinic as a pre-doctoral fellow and post-doctoral fellow in Cardiovascular Diseases and a second pre-doctoral fellowship in Nephrology and Hypertension. He was an assistant professor in the College of Pharmacy at the University of Arizona and then moved on to the University of Minnesota before co-founding Geneticure.

Ryan Sprissler, PhD

CHIEF SCIENTIFIC OFFICER

Dr. Sprissler is a founding member of the Center for Applied Genetics and Genomic Medicine and Lead Scientist managing the University of Arizona Genetics Core facility specializing in cutting edge genomic technology. An industry pioneer, he has leveraged several partnerships fueling the high growth industry of genomic testing. With 15 years of experience in genetic assay design/testing he is a current member of the Association for Bioresource Facilities (ABRF), the Association for Laboratory Automation (ALA) & the American Association for the Advancement of Science (AAAS).

Thomas Olson, PhD

CHIEF CLINICAL OFFICER

Dr. Olson is an Associate Professor of Medicine and Science and Consultant in the Department of Cardiovascular Medicine at Mayo Clinic where he sees patients in the Division of Preventive Cardiology. He is the Director of the Clinical Integrative Physiology Research Laboratory which is funded by the National Institutes of Health, American Heart Association, and Industry.

Timothy Curry, MD, PhD

MEDICAL DIRECTOR

Dr. Curry has lead large clinical pharmacogenomic implementation projects and is a leader in pharmacogenomic education. He is the Director of the Education Program of the Mayo Clinic Center for Individualized Medicine as well as the Vice Chair of Practice for the Department of Anesthesiology and Perioperative Medicine, also at Mayo Clinic. He is also an integrative physiologist with special expertise in cardiopulmonary and neural physiology.

Monica Akre, PhD

DIRECTOR OF LABORATORY DEVELOPMENT

Dr. Akre spent 6 years in the Cytogenetics department at Mayo Clinic before moving to the University of Minnesota for graduate studies where she worked on identification of pharmacogenomic biomarkers. Her focus is to ensure expansion of personalized medicine to promising ventures. Current focus is prediction of drug response in hematologic malignancies.

Dr. Bonny Lewis Van, PhD

Laboratory Director

Dr. Lewis Van completed her award-winning clinical laboratory fellowship at the University of Louisville, with an emphasis on pharmacogenetics. She has been on the faculty of Virginia Commonwealth University with appointments in Pharmacy, Pathology and Anesthesiology as well as being a member of the Bioinformatics faculty. Bonny helped to create a nation-wide pharmacogenetic company, and currently holds several leadership positions in the American Association for Clinical Chemistry (AACC), American Association of Bioanalysts (AAB) and the American Board of Bioanalysis (ABB) and is a Clinical Laboratory Informatics Lead for J Michael Consulting.

Dr. Bronwyn Ramey Hartung, PhD

Laboratory Director

Dr. Ramey-Hartung, PhD, HCLD (ABB) has worked in research and commercial genetics laboratories for 20 years. She was deeply involved in the growth and operation of one of the first laboratories CLIA-certified specifically to perform pharmacogenetic tests and has since built an expansive portfolio of new pharmacogenetics laboratories. She holds a Certificate of Qualification for pharmacogenetics in New York state and is HCLD-certified by the American Association of Bioanalysts. She lives with her husband and rambunctious sons in the rolling bluegrass east of Louisville, Kentucky.

A new era in pharmacogenomics, driven by evidence and measurable outcomes.

At Geneticure, we’re changing the way costly and deadly diseases are being treated by using each patient’s DNA to predict their response to medications. Driven by a passion for evidence-driven improvements beyond one-size-fits-all healthcare, we partner with patients, caregivers, employers, and healthcare providers to deliver more effective treatments. Uniquely supported by rigorous clinical trials and economic evidence, our tests provide answers that we hope will eliminate millions of unnecessary prescriptions, strokes, heart attacks, days of missed work, and preventable deaths, worldwide.

For more information on how you can participate as an investor or industry partner, please contact us today.

Careers

Our company is in the midst of extraordinary growth and looking for experienced professionals with a passion for excellence. To be considered, please contact us.

Your questions answered.

Please visit our Frequently Asked Questions for more information about Geneticure.